Latest News

Oral PCSK9 Inhibitor Enlicitide Meets All Endpoints in Phase 3 Hypercholesterolemia Trial
Oral PCSK9 Inhibitor Enlicitide Meets All Endpoints in Phase 3 Hypercholesterolemia Trial

September 2nd 2025

At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD / Image credit: ©Corona Borealis/AdobeStock
Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD

September 2nd 2025

American College of Cardiology: How to Address Barrier to Immunization for Adults with CVD / image credit ©MAKOVSKY ART/stock.adobe.com
American College of Cardiology: How to Address Barriers to Immunization for Adults with CVD

August 28th 2025

Shingles Vaccine Linked to Reduced Cardiovascular Risk in Global Meta-Analysis: ESC Preview / image credit ©Sherry Young/stock.adobe.com
Shingles Vaccine Linked to Reduced Cardiovascular Risk in Global Meta-Analysis: ESC Preview

August 28th 2025

FDA Expands Evolocumab Indication to Adults at Risk for Major Cardiovascular Events Due to Uncontrolled LDL-C
FDA Expands Evolocumab Indication to Adults at Risk for Major Cardiovascular Events Due to Uncontrolled LDL-C

August 26th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.